Letter by Lewis and Miller Regarding Article, “Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved Ejection Fraction”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
This outstanding article by Methawasin et al1 provides further insights into the potential role of titin isoform manipulation in forming future therapeutic targets for diastolic dysfunction and the heart failure with preserved ejection fraction (HFpEF) syndrome. In asking whether a similar impact could be expected in the human HFpEF population, several questions arise. The authors note that the degree of diastolic dysfunction in the mouse model represents restrictive physiology, with the mean mitral valve E/A ratio of 2.46 in the cRbm20 …